CROSS COUNTRY HEALTHCARE INC (CCRN) Stock Fundamental Analysis
NASDAQ:CCRN - Nasdaq - US2274831047 - Common Stock - Currency: USD
CCRN gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 103 industry peers in the Health Care Providers & Services industry. CCRN has a great financial health rating, but its profitability evaluates not so good. CCRN is valied quite expensively at the moment, while it does show a decent growth rate.
1. Profitability
1.1 Basic Checks
CCRN had positive earnings in the past year.
In the past year CCRN had a positive cash flow from operations.
The reported net income has been mixed in the past 5 years: CCRN reported negative net income in multiple years.
Of the past 5 years CCRN 4 years had a positive operating cash flow.
1.2 Ratios
Looking at the Return On Assets, with a value of -3.08%, CCRN is doing worse than 60.19% of the companies in the same industry.
CCRN has a Return On Equity of -4.24%. This is comparable to the rest of the industry: CCRN outperforms 46.60% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.08% | ||
| ROE | -4.24% | ||
| ROIC | N/A |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of CCRN has declined.
Looking at the Gross Margin, with a value of 20.32%, CCRN is doing worse than 60.19% of the companies in the same industry.
In the last couple of years the Gross Margin of CCRN has declined.
CCRN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.32% |
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
2. Health
2.1 Basic Checks
CCRN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CCRN has less shares outstanding
The number of shares outstanding for CCRN has been reduced compared to 5 years ago.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 4.63 indicates that CCRN is not in any danger for bankruptcy at the moment.
CCRN has a Altman-Z score of 4.63. This is amongst the best in the industry. CCRN outperforms 80.58% of its industry peers.
CCRN has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 4.63 |
ROIC/WACCN/A
WACC9.07%
2.3 Liquidity
CCRN has a Current Ratio of 2.98. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
CCRN has a better Current ratio (2.98) than 87.38% of its industry peers.
CCRN has a Quick Ratio of 2.98. This indicates that CCRN is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 2.98, CCRN belongs to the top of the industry, outperforming 87.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.98 |
3. Growth
3.1 Past
The earnings per share for CCRN have decreased strongly by -79.49% in the last year.
CCRN shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 24.57% yearly.
The Revenue for CCRN has decreased by -29.16% in the past year. This is quite bad
CCRN shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.33% yearly.
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%
3.2 Future
CCRN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.79% yearly.
The Revenue is expected to decrease by -0.05% on average over the next years.
EPS Next Y-30.71%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue Next Year-11.63%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
Based on the Price/Earnings ratio of 37.75, the valuation of CCRN can be described as expensive.
CCRN's Price/Earnings ratio is in line with the industry average.
When comparing the Price/Earnings ratio of CCRN to the average of the S&P500 Index (27.52), we can say CCRN is valued slightly more expensively.
Based on the Price/Forward Earnings ratio of 24.42, the valuation of CCRN can be described as rather expensive.
CCRN's Price/Forward Earnings is on the same level as the industry average.
CCRN is valuated rather cheaply when we compare the Price/Forward Earnings ratio to 35.58, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.75 | ||
| Fwd PE | 24.42 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of CCRN is on the same level as its industry peers.
Based on the Price/Free Cash Flow ratio, CCRN is valued cheaply inside the industry as 97.09% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 3.55 | ||
| EV/EBITDA | 24.55 |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)1.54
EPS Next 2Y4.85%
EPS Next 3Y10.79%
5. Dividend
5.1 Amount
CCRN does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
12.08
+0.01 (+0.08%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners99.95%
Inst Owner Change0%
Ins Owners5.71%
Ins Owner Change-0.22%
Market Cap395.98M
Analysts52.31
Price Target18.44 (52.65%)
Short Float %5.96%
Short Ratio7.17
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-30.26%
Min EPS beat(2)-66.11%
Max EPS beat(2)5.59%
EPS beat(4)2
Avg EPS beat(4)-16.07%
Min EPS beat(4)-66.11%
Max EPS beat(4)22.23%
EPS beat(8)5
Avg EPS beat(8)-5.82%
EPS beat(12)9
Avg EPS beat(12)-0.39%
EPS beat(16)13
Avg EPS beat(16)7.65%
Revenue beat(2)0
Avg Revenue beat(2)-3.28%
Min Revenue beat(2)-5.84%
Max Revenue beat(2)-0.73%
Revenue beat(4)0
Avg Revenue beat(4)-1.87%
Min Revenue beat(4)-5.84%
Max Revenue beat(4)-0.41%
Revenue beat(8)1
Avg Revenue beat(8)-1.29%
Revenue beat(12)4
Avg Revenue beat(12)-0.29%
Revenue beat(16)8
Avg Revenue beat(16)1.65%
PT rev (1m)0%
PT rev (3m)-2.83%
EPS NQ rev (1m)-5.91%
EPS NQ rev (3m)-38.35%
EPS NY rev (1m)-15.08%
EPS NY rev (3m)-23.84%
Revenue NQ rev (1m)-0.22%
Revenue NQ rev (3m)-4.71%
Revenue NY rev (1m)-1.47%
Revenue NY rev (3m)-4.81%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 37.75 | ||
| Fwd PE | 24.42 | ||
| P/S | 0.31 | ||
| P/FCF | 3.55 | ||
| P/OCF | 3.31 | ||
| P/B | 0.95 | ||
| P/tB | 1.63 | ||
| EV/EBITDA | 24.55 |
EPS(TTM)0.32
EY2.65%
EPS(NY)0.49
Fwd EY4.1%
FCF(TTM)3.4
FCFY28.13%
OCF(TTM)3.65
OCFY30.25%
SpS38.38
BVpS12.76
TBVpS7.42
PEG (NY)N/A
PEG (5Y)1.54
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -3.08% | ||
| ROE | -4.24% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 20.32% | ||
| FCFM | 8.85% |
ROA(3y)9.37%
ROA(5y)8.5%
ROE(3y)17.7%
ROE(5y)17.81%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)21.31%
ROCE(5y)19.23%
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-77.97%
OM growth 5Y-33.84%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.01%
GM growth 5Y-3.83%
F-Score4
Asset Turnover2.18
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 45.77% | ||
| Cap/Sales | 0.67% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 933.79% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.98 | ||
| Quick Ratio | 2.98 | ||
| Altman-Z | 4.63 |
F-Score4
WACC9.07%
ROIC/WACCN/A
Cap/Depr(3y)64.63%
Cap/Depr(5y)60.57%
Cap/Sales(3y)0.55%
Cap/Sales(5y)0.53%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-79.49%
EPS 3Y-47.22%
EPS 5Y24.57%
EPS Q2Q%-68.42%
EPS Next Y-30.71%
EPS Next 2Y4.85%
EPS Next 3Y10.79%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.16%
Revenue growth 3Y-7.11%
Revenue growth 5Y10.33%
Sales Q2Q%-22.62%
Revenue Next Year-11.63%
Revenue Next 2Y-3.2%
Revenue Next 3Y-0.05%
Revenue Next 5YN/A
EBIT growth 1Y-106.89%
EBIT growth 3Y-79.54%
EBIT growth 5Y-27.01%
EBIT Next Year706.57%
EBIT Next 3Y126.18%
EBIT Next 5YN/A
FCF growth 1Y-44.19%
FCF growth 3YN/A
FCF growth 5Y112.02%
OCF growth 1Y-42.96%
OCF growth 3YN/A
OCF growth 5Y85.29%